Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.
Jiao YangJie HuangGongjun YuanXiao-Cheng LinHua-Jun ChenJin-Ji YangPublished in: Clinical case reports (2024)
G12C-mutated patient may favor the immunotherapy.
Keyphrases